Jazz Pharmaceuticals

Valuation Analysis

About the Company

Jazz Pharmaceuticals en bref

Jazz Pharmaceuticals (JAZZ) is currently trading at 219,74 € with a market capitalization of 13,8 Md €. The trailing P/E ratio stands at 2528.6x, with a forward P/E of 9.83x. The 52-week range spans from 91,25 € to 227,08 €; the current price is 3.2% below the yearly high. Year-over-year revenue growth stands at +19.1%. The net profit margin stands at 0.66%.

💰 Dividende

Jazz Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

20 analystes évaluent Jazz Pharmaceuticals (JAZZ) au consensus : Acheter. L'objectif de cours moyen est de 231,95 €, soit un potentiel de +5.55% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 170,33 € à 266,79 €.

Jazz Pharmaceuticals : la thèse d'investissement en détail

Jazz Pharmaceuticals (JAZZ) operates in the Healthcare — specifically Biotechnology — and is headquartered in Ireland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 19.1% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 91.5%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

With a net margin of just 0.66%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

With a PEG ratio of 0.96, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 9.17x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 9.83x is meaningfully below the trailing 2528.6x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 94.6% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (6.24%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Jazz Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.